. 2021 Apr 29;11(5):809. doi: 10.3390/diagnostics11050809

Table 3.

Weeks to virological-suppression across treatment groups and baseline strata in observed analysis from GEMINI-1 and -2 clinical trials.

Observed Analysis at 96-Weeks ^a		Weeks to HIV-1 RNA <40 Copies/mL and Target Not Detected, Median	95% Confidence Intervals
DTG+3TC, N = 616		8	NE, NE
DTG+TDF/FTC, N = 642		8	NE, NE
Baseline subgroups
VL ≤ 100,000 c/mL	DTG+3TC, N = 499	8	(~8, ~8)
VL ≤ 100,000 c/mL	DTG+TDF/FTC, N = 510	8	(~8, ~8)
VL > 100,000 c/mL	DTG+3TC, N = 117	16	(~16, ~24)
VL > 100,000 c/mL	DTG+TDF/FTC, N = 132	24	(~24, ~36)
CD4+ cells >200 cells/mm³	DTG+3TC, N = 573	8	(NE, NE)
CD4+ cells >200 cells/mm³	DTG+TDF/FTC, N = 594	8	(NE, NE)
CD4+ cells ≤200 cells/mm³	DTG+3TC, N = 43	16	(~12, ~24)
CD4+ cells ≤200 cells/mm³	DTG+TDF/FTC, N = 48	12	(~8, ~24)

^a Observed analysis includes subjects virologically suppressed at 96-weeks, and thereby censors earlier failures including those unrelated to efficacy. 3TC = lamivudine; DTG = dolutegravir; FTC = emtricitabine; NE = not evaluable; TDF = tenofovir disoproxil fumarate; VL = viral load.